CN101023976B - Medicine composition with anti-virus function - Google Patents
Medicine composition with anti-virus function Download PDFInfo
- Publication number
- CN101023976B CN101023976B CN2007100864244A CN200710086424A CN101023976B CN 101023976 B CN101023976 B CN 101023976B CN 2007100864244 A CN2007100864244 A CN 2007100864244A CN 200710086424 A CN200710086424 A CN 200710086424A CN 101023976 B CN101023976 B CN 101023976B
- Authority
- CN
- China
- Prior art keywords
- echinacea
- radix astragali
- ethanol
- preparation
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims description 18
- 229940079593 drug Drugs 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 title claims description 7
- 230000002155 anti-virotic effect Effects 0.000 title description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 229940107666 astragalus root Drugs 0.000 claims abstract description 4
- 239000009636 Huang Qi Substances 0.000 claims description 43
- 235000014134 echinacea Nutrition 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 235000020694 echinacea extract Nutrition 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 13
- 241000712461 unidentified influenza virus Species 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000005325 percolation Methods 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241000258180 Echinacea <Echinodermata> Species 0.000 claims 2
- 238000000227 grinding Methods 0.000 claims 2
- 238000007873 sieving Methods 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 244000133098 Echinacea angustifolia Species 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000009471 action Effects 0.000 description 10
- 241000700605 Viruses Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 5
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 5
- 241000545442 Radix Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 5
- 229930016920 cichoric acid Natural products 0.000 description 5
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 description 5
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000010231 banlangen Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229940039673 echinacea preparation Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 229960002194 oseltamivir phosphate Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000189115 Catananche Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000009571 yupingfeng Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a compound preparation by using (by weight portion) 1-3 portions of Chinese medicinal plant Zizhuiju and 1-3 portions of astragalus root. Said compound preparation has the antiviral action. Besides, said invention also provides its preparation method and concrete steps.
Description
Technical field
The present invention relates to the field of Chinese medicines, specifically provide a kind of pharmaceutical composition with antivirus action.And each proportion raw material has the health food of antivirus action and the purposes in the medicine in preparation.
Background technology
Virus distributes very wide at occurring in nature, be one of important pathogen that causes the human infectious disease.In the mankind's infectious disease, what caused by virus is many far beyond antibacterial and other microorganisms, accounts for 3/4, and as influenza, hepatitis, epidemic hemorrhagic fever, chickenpox, herpes zoster and acquired immune deficiency syndrome (AIDS) etc., infectiousness is strong, popular extensively.Virus is also relevant with some tumor, congenital malformation, senile dementia etc.
The Radix Astragali (Astragalus membranaceus (Fisch) Bunge) beginning is stated from Shennong's Herbal and classifies as top gradely, is the root of the leguminous plant Radix Astragali or Radix Astagali.Radix Astragali sweet in the mouth, tepor are gone into lung, spleen channel, have the effect that benefit is defended the consolidating superficial resistance invigorating the spleen and replenishing QI.In motherland's medical science, be widely used in the tonification prescription.Cure mainly exterior deficiency, hyperhidrosis easy catching a cold as the Radix Astragali as the YUPINGFENG SAN of monarch drug.Radix Astragali sales volume on international medical herbs market improves constantly in recent years, is listed in preceding 20 kinds of best-selling medical herbs at the North America market Radix Astragali in 2000.
The Radix Astragali has the effect of significant adjusting body's immunity, and astragalus polysaccharides (APS) is the effective ingredient of the Radix Astragali, has many-sided immunological enhancement, can not only strengthen and regulate immunologic function, also has dual regulation.The Radix Astragali can improve body resistance against diseases, antibiotic, antiviral, antiphlogistic effect are arranged again, can strengthen simultaneously the effect of the phagocytic function of reticuloendothelial cell, the enhancing non-specific immunity function, blood middle leukocytes sum and multinuclear leucocyte digital display work is increased, improve the ability of body inducement interferon, promote body antibody to generate.
Echinacea (Echinacea purpurea) has another name called Echinacea Species, SONGGUOJU, is American Indian's traditional herbal medicines originally, is a kind of catananche, is mainly used in diseases such as wound, various types of infection and venom.1916, Echinacea was put into American Pharmacopeia, and earlier 1900s, Echinacea enters Europe, and caused extensive attention.
Contain multiple important pharmaceutical component in the Echinacea, mainly contain caffeic acid derivant, polysaccharide, poly acetylene, alkylamide and other chemical compounds.To Echinacea widely pharmaceutical research show the hyaluronidase that Echinacea extract can directly suppress to organize and pathogen produces, thereby increase hyaluronic stability, keep the integrity of the structure of connective tissue and intercellular stroma thereof; Echinacea can improve numeration of leukocyte when serum leukocyte number is low.Studies show that Echinacea extract is incorporated on the receptor of leukocyte surface and then has activated these cells.To the most responsive leukocyte of Echinacea is T-lymphocyte, macrophage and natural killer cell.Echinacea extract has inhibitory action to influenza virus, herpesvirus, poliovirus and vesicular stomatitis virus in addition.
Clinical research is the result show, the Echinacea preparation has the raising immune function of human body, flu-prevention and respiratory tract infection, for the upper respiratory tract bacterial infection patients (mainly is pharyngitis, tonsillitis), the Echinacea preparation can make medication group patient obviously accelerate recovery from illness, and relapse rate obviously reduces.Toxicological study shows that Echinacea and multiple extract toxicity thereof are extremely low, safe.But remarkable (the Barrett B P of effect that also has report to think that the Echinacea treatment is caught a cold in Britain ... //Ann Intern Med ... 2002,137 (12) .939～945).
Chinese patent CN1473602 disclosed alcohol reflux, remove impurity in 2004, has concentrated, vacuum drying, and upper prop prepares the method for chicoric acid (main component of Echinacea) again through the membrane filtration edulcoration purification.Chinese patent CN1587251 disclosed and adopts technical processs such as organic solvent extraction, acidify, solvent extraction, resin isolation, solvent crystallization to prepare the method for chicoric acid in 2006.Chinese patent CN1552350 discloses a kind ofly with Folium Isatidis, and Radix Isatidis, Echinacea, vegetable Chinese herbal medicine extracts such as Radix Scutellariae are the anti-Chinese medicine preparation that cures cold of raw material.
Chinese patent CN17040885A disclosed the Radix Astragali in 2005 and Echinacea extract is the pharmaceutical composition that raw material is made, and the oral formulations of this pharmaceutical composition is applied to improve immunity of organisms.
These two kinds of medicines use the Pharmacological action study report of antagonism virus a lot of separately, and only are used for human body immunity improving power at present by the compound preparation that these two kinds of medicines are formed, and do not have antiviral pharmacological action to see report, comprise the effect of resisiting influenza virus.
Summary of the invention
The present invention will disclose is to be the new pharmacological action of the compound preparation made of raw material with the Chinese crude drug Radix Astragali and natural drug Echinacea extract: antivirus action makes this compound preparation can be applicable to new purposes except that improving immunity.Drug effect that the Radix Astragali and Echinacea extract are good and high safety have certain effect for the situation of the low drug effect of the many toxic and side effects of improving chemical synthetic drug in the present antiviral drugs and Chinese medicine compound preparation.
The preparation of drug combination method of the Radix Astragali of the present invention and Echinacea, its main technique step is:
1, the preparation of Radix Astragali extract: astragalus root dries after washing.Add 30% soak with ethanol behind the crushing screening, spend the night, the ethanol with 10 times of amounts 30% carries out percolation at ambient temperature, the standing over night after-filtration, and filtrate decompression is carried out vacuum drying after concentrating, and dry thing is pulverized the back and is crossed 60 mesh sieves promptly.
2, the preparation of Echinacea extract: the Echinacea root dries after washing.Add 55% soak with ethanol behind the crushing screening, spend the night, the ethanol of 10 times of amounts 55% carries out percolation at ambient temperature, the standing over night after-filtration, and filtrate decompression is carried out vacuum drying after concentrating, and dry thing is pulverized the back and is crossed 60 mesh sieves promptly.
3, the processing of finished product: with the extract dry powder of the Radix Astragali and Echinacea mix homogeneously by a certain percentage, mixed-powder after the assay was approved directly or add a certain amount of pharmaceutic adjuvant or substrate is processed into various dosage forms promptly, as tablet, granule, capsule, soft capsule, preparations such as drop pill.The substrate here can be drop pill substrate such as Polyethylene Glycol.
For verifying reliability of the present invention, use the ICR mice to carry out two antivirus tests.
Test one: Echinacea and Radix Astragali extract are to the influence of influenza virus Lung Index of mice infected by Influenza virus
Get 220 of the ICR mices of 17～19g, male and female half and half, be divided into 11 groups at random by body weight, be blank group, model control group, sample A (Echinacea extract) group, sample B (Radix Astragali extract) group, sample C (B+A) group, sample D (3B+A) group, sample E (B+3A) group, sample F (B+2A) group, sample G (2B+A) group, positive reference substance 1 group of (oseltamivir phosphate capsule) and 2 groups of positive reference substances (Radix Isatidis granule).Each is organized the beginning in preceding 3 days of mice self-infection virus and gives relative medicine every day, observes the influence to the influenza virus Lung Index of mice infected by Influenza virus of the Echinacea of different proportionings and Radix Astragali extract.And with positive drug 15mgkg
-1Oseltamivir phosphate capsule and 10gkg
-1Radix Isatidis granule compares.
Experimental result (table 1) finds that except that independent use Echinacea group, all the other each test group all can suppress the lung index of influenza first type PR8 infecting mouse, with model group comparing difference remarkable (P＜0.01); Its action effect all is better than 10gkg
-1Radix Isatidis granule, but be weaker than 15mgkg
-1Oseltamivir phosphate capsule; In the different proportionings with Radix Astragali extract of Echinacea, the effect of 3 Radixs Astragali+Echinacea, the Radix Astragali+2 Echinaceas, 2 Radixs Astragali+Echinacea assembly ratio is better, wherein 2 Radixs Astragali+Echinacea group best results.
Above result of the test shows that the Echinacea of different proportionings and Radix Astragali extract have interior resisting virus effect preferably, and wherein 2 Radixs Astragali+Echinacea group is to the exponential inhibitory action the best of mice influenza infection lung.
Table 1 Echinacea extract and Radix Astragali extract are to the influence of influenza A virus PR8 Lung Index of mice infected by Influenza virus
Annotate: compare Δ P＜0.05, Δ Δ P＜0.01 with the normal control group; Compare * P＜0.05, * * P＜0.01 with model control group
Test two: Echinacea and Radix Astragali extract are to the protection test of influenza virus infection in the mice body
A same test of experimental animal and blank group, model control group and sample sets, positive controls is an oseltamivir phosphate capsule.Each is organized the beginning in preceding 3 days of mice self-infection virus and gives relative medicine every day, observes the protective effect to influenza virus infection in the ICR mice body of the Echinacea of different proportionings and Radix Astragali extract, and with positive drug 15mgkg
-1Oseltamivir phosphate capsule compares.
Result of the test (table 2, table 3) shows, gives the Echinacea and the Radix Astragali extract of different proportionings, can effectively reduce the influenza infection mortality of mice, improves the dead protective rate of mice, prolongs vital rates.In the different proportionings of Echinacea and Radix Astragali extract, the action effect of the 3 Radixs Astragali+Echinacea and the Radix Astragali+2 Echinacea proportionings is preferable, is better than the Radix Astragali group and the Echinacea group of use separately, but is weaker than 15mgkg
-1Oseltamivir phosphate capsule.
In sum, pharmaceutical composition provided by the invention has better antivirus action than the preparation of the single Echinacea and the single Radix Astragali.As seen Echinacea and Radix Astragali extract have synergism, and both are used in combination the obvious antivirus action that strengthens the single preparation.
Table 2 Echinacea extract and Radix Astragali extract are to the influence of influenza A virus PR8 infecting mouse (♂)
Table 3 Echinacea extract and Radix Astragali extract are to the influence of influenza A virus PR8 infecting mouse (♀)
Annotate: compare Δ P＜0.05, Δ Δ P＜0.01 with the normal control group; Compare * P＜0.05, * * P＜0.01 with model control group
The specific embodiment:
Embodiment 1: the Radix Astragali and Echinacea extract preparation
1, the preparation of Radix Astragali extract: astragalus root dries after washing.Add 30% soak with ethanol behind the crushing screening, spend the night, the ethanol that adds 10 times of amounts 30% at ambient temperature carries out percolation, the standing over night after-filtration, and filtrate decompression is carried out vacuum drying after concentrating, and dry thing is pulverized the back and is crossed 60 mesh sieves promptly.
2, the preparation of Echinacea extract: the Echinacea root dries after washing.Add 55% soak with ethanol behind the crushing screening, spend the night, the ethanol that adds 10 times of amounts 55% at ambient temperature carries out percolation, the standing over night after-filtration, and filtrate decompression is carried out vacuum drying after concentrating, and dry thing is pulverized the back and is crossed 60 mesh sieves promptly.
Embodiment 2: substantially the same manner as Example 1, different is to carry out percolation with ethanol water in the leaching process under the condition of higher temperature (greater than 50 ℃).
Embodiment 3: the capsular preparation of the Radix Astragali and Echinacea extract
The Radix Astragali and the Echinacea extract dry powder that prepare is even by 1: 1 mixed, and mixed-powder is through incapsulating promptly after the assay was approved.
Embodiment 4: substantially the same manner as Example 3, different is that the Radix Astragali and Echinacea extract dry powder are even by 1: 2 mixed.
Embodiment 5: substantially the same manner as Example 3, different is that the Radix Astragali and Echinacea extract dry powder are even by 1: 3 mixed.
Embodiment 6: substantially the same manner as Example 3, different is that the Radix Astragali and Echinacea extract dry powder are even by 2: 1 mixed.
Embodiment 7: substantially the same manner as Example 3, different is that the Radix Astragali and Echinacea extract dry powder are even by 3: 1 mixed.
Embodiment 8: the capsular assay of the Radix Astragali and Echinacea extract
1, the assay of astragaloside (ultraviolet-visible spectrophotography)
Method: the about 1.0g of sample thief adds about 40ml water, 60 ℃ of supersound extraction 40min, take out, put coldly, water is settled to 50ml, filter, get 1.0ml filtrate and cross macroporous resin (earlier with the activation of 40ml 80% ethanol), use the 30ml water washing, abandon cleaning mixture, with 80% ethanol 25ml, the eluting saponin is collected eluent, and 80 ℃ of water-baths volatilize, add 0.2ml 5% vanillin glacial acetic acid solution, 0.8ml perchloric acid, mixing, 60 ℃ of heating in water bath 10min, add the 5ml glacial acetic acid, shake up, in L=1cm, wavelength=560nm place measures trap.
Get astragaloside standard solution (2.0mg/ml) 10.0,20.0,40.0,60.0,80.0,100.0 μ l, water-bath volatilizes, and adds 0.2ml 5% vanillin glacial acetic acid solution, and as follows sample determination is measured trap drawing standard curve.
Calculate: the content of astragaloside=(from marking content * 50 that song checks in)/(accurate amount * 1000 that claim the random sample product)
2, the assay of chicoric acid (high performance liquid chromatogram algoscopy)
Chromatographic condition: Hypersil C18 post is a mobile phase with acetonitrile-0.1% phosphoric acid water, and gradient elution, flow velocity are 1.0ml/min, and the detection wavelength is 330nm, and sample size is 10 μ l.
The preparation of titer: precision takes by weighing chicoric acid reference substance 5mg, puts in the brown volumetric flask of 50ml, adds a little methanol of 70%, ultrasonic dissolution, and flowing water is cooled to room temperature then, and 70% methanol constant volume shakes up standby to scale.
Sample preparation: precision takes by weighing sample 0.1g, puts in the brown volumetric flask of 50ml, adds a little methanol of 70%, ultrasonic dissolution, and flowing water is cooled to room temperature then, and 70% methanol constant volume shakes up to scale, accesses filtrate for later use with 0.45 μ m microporous filter membrane then.
Calculate: press the peak area external standard and calculate content
The content of chicoric acid=((sample peak area/standard substance peak area) * standard substance concentration (mg/ml) * constant volume (ml))/(amount of 1000 * sample (g)) * 100.
Claims (1)
1. a compositions has the health food of resisiting influenza virus effect or the purposes in the medicine in preparation, it is characterized in that the crude drug of said composition is the Radix Astragali and Echinacea, and preparation method may further comprise the steps:
A: astragalus root dries after washing; Crushing screening adds 30% soak with ethanol, spends the night, and add 30% ethanol at ambient temperature and carry out percolation, the standing over night after-filtration, filtrate decompression is carried out vacuum drying after concentrating, and dry thing grinding and sieving is promptly;
B: the Echinacea root dries after washing; Crushing screening adds 55% soak with ethanol, spends the night, and add 55% ethanol at ambient temperature and carry out percolation, the standing over night after-filtration, filtrate decompression is carried out vacuum drying after concentrating, and dry thing grinding and sieving is promptly;
C: with 2 parts in above-mentioned Radix Astragali extract powder, 1 part of mixing of Echinacea extract powder, directly or add the medicament that acceptable adjuvant is pharmaceutically made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100864244A CN101023976B (en) | 2006-10-26 | 2007-03-08 | Medicine composition with anti-virus function |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610053975.6 | 2006-10-26 | ||
| CNA2006100539756A CN1943609A (en) | 2006-10-26 | 2006-10-26 | Medicinal composition with anti-virus function and its preparing method |
| CN2007100864244A CN101023976B (en) | 2006-10-26 | 2007-03-08 | Medicine composition with anti-virus function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101023976A CN101023976A (en) | 2007-08-29 |
| CN101023976B true CN101023976B (en) | 2011-01-26 |
Family
ID=38742818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100864244A Active CN101023976B (en) | 2006-10-26 | 2007-03-08 | Medicine composition with anti-virus function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101023976B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112691135A (en) * | 2021-02-06 | 2021-04-23 | 江南大学 | Anti-tumor traditional Chinese medicine composition and application thereof |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869706A (en) * | 2010-06-24 | 2010-10-27 | 西北农林科技大学 | A compound astragalus polysaccharide and echinacea extract nanoemulsion adjuvant and its preparation method |
| CN103518963B (en) * | 2013-09-28 | 2015-02-18 | 石家庄江山饲料有限公司 | Additive for livestock feed |
| CN103638092A (en) * | 2013-12-11 | 2014-03-19 | 安广路 | Animal immune regulator |
| CN106038725A (en) * | 2016-07-16 | 2016-10-26 | 周长征 | Method for separating anti-RSV-virus effective constituents after compatibility of pulsatilla chinensis and holotrichia diomphalia extracts |
| CN106389788B (en) * | 2016-11-14 | 2019-09-13 | 青岛农业大学 | A medicinal extract, preparation and preparation method for enhancing the immune function and antiviral ability of livestock and poultry |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704085A (en) * | 2004-06-04 | 2005-12-07 | 成都地奥制药集团有限公司 | Pharmaceutical composition with immunoregulation function and method for preparing the same |
-
2007
- 2007-03-08 CN CN2007100864244A patent/CN101023976B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704085A (en) * | 2004-06-04 | 2005-12-07 | 成都地奥制药集团有限公司 | Pharmaceutical composition with immunoregulation function and method for preparing the same |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112691135A (en) * | 2021-02-06 | 2021-04-23 | 江南大学 | Anti-tumor traditional Chinese medicine composition and application thereof |
| CN112691135B (en) * | 2021-02-06 | 2022-03-25 | 江南大学 | Anti-tumor traditional Chinese medicine composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101023976A (en) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101023976B (en) | Medicine composition with anti-virus function | |
| CN100457139C (en) | Method for preparing a Shuanhuanglian injection and the component detecting method | |
| CN1872106A (en) | Application of wild basil circle leaves in treating disease of virulence cold | |
| WO2010099613A1 (en) | Plant extract compositions for prevention and treatment of influenza | |
| CN103099838A (en) | Anti-hepatitis B virus composition taken from fresh dandelion and application of anti-hepatitis B virus composition in preparation of anti-hepatitis B virus drug | |
| CN102210737B (en) | Sweet potato leaf extract and preparation method and use thereof | |
| CN100584348C (en) | Anti-hepatitis medical combination | |
| CN103285230B (en) | Pharmaceutical composition for treating pharyngitis and preparation method thereof | |
| CN102805767A (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN1943609A (en) | Medicinal composition with anti-virus function and its preparing method | |
| CN1973853B (en) | Hemostatic and analgetic medicine composition and its preparation process | |
| CN1957999B (en) | Composition of Chinese traditional medicine, preparation method, and checking method | |
| CN104352531B (en) | Application of the swinging seat nematode grass in hepatic and health products is prepared | |
| CN105381362A (en) | Composition for preventing and treating alcoholic liver injury and relieving alcoholism | |
| CN102697800B (en) | Herba stellariae mediae polysaccharide composition and the application in preparation antiviral drugs thereof | |
| CN1803179B (en) | Traditional Chinese medicine composition and its preparation method and quality control method | |
| CN1323682C (en) | Chinese medicine preparation of infectious external contraction high fever and production thereof | |
| CN101167799B (en) | Scutellaria barbata total flavone and its application in preparing influenza virus resisting medicine | |
| CN113101331A (en) | A kind of thyme medicinal tea and its preparation method and application | |
| CN101429187A (en) | Ketone compound, preparation method and application thereof | |
| CN105497156A (en) | Preparation method of fleeceflower root life-extending preparation | |
| CN105168612A (en) | Drug for treating piglet diarrhea, as well as preparation method, detection method and application thereof | |
| CN113648357B (en) | Application of traditional Chinese medicine composition in preparation of anti-inflammatory drugs and/or immunoregulation drugs | |
| CN113398189B (en) | Application of traditional Chinese medicine composition in preparation of anti-influenza virus medicine | |
| CN113499384B (en) | Traditional Chinese medicine composition, pharmaceutical preparation, preparation method of pharmaceutical preparation and application of pharmaceutical preparation in resisting coronavirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |